Bioscience Holdings News Today

Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS – Get Free Report) was the target of a large drop in short interest during the month of December. As of December 31st, there was short interest totalling 89,000 shares, a drop of 79.8% from the December 15th total of 440,300 shares. Based on an average daily volume of 1,643,300 […]

Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS – Get Free Report) saw a large drop in short interest in December. As of December 31st, there was short interest totalling 89,000 shares, a drop of 79.8% from the December 15th total of 440,300 shares. Based on an average daily trading volume, of 1,643,300 shares, the short-interest ratio is […]

Key Insights Insiders appear to have a vested interest in Regencell Bioscience Holdings' growth, as seen by their...

We can readily understand why investors are attracted to unprofitable companies. For example, although...

/PRNewswire/ -- The "Skin Substitutes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type (Biological v/s...

Key Insights Regencell Bioscience Holdings' significant insider ownership suggests inherent interests in company's...

Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS – Get Free Report) saw a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 234,400 shares, a drop of 69.9% from the June 15th total of 779,800 shares. Based on an average trading volume of 1,474,500 shares, the days-to-cover […]

/PRNewswire/ -- The "Europe Alzheimers Disease Therapeutics and Diagnostics Market 2022-2028" report has been added to ResearchAndMarkets.coms offering. This...

Amarantus BioScience Holdings, Inc. (OTCMKTS:AMBS – Get Rating) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 16,000 shares, a growth of 52.4% from the March 31st total of 10,500 shares. Based on an average daily trading volume, of 3,506,400 […]

Regencell Bioscience Holdings Limited gibt Preis von rund 21,9 Millionen US-Dollar für seinen Börsengang bekannt 17.07.2021 | 02:12 Quelle: Business Wire HONGKONG--(BUSINESS WIRE)--Regencell Bioscience Holdings Limited (NASDAQ:RGC) („Regencell“ oder das „Unternehmen“), ein junges Biotechnologie-Unternehmen, das sich auf Forschung, Entwicklung und Vermarktung traditioneller chinesischer Medizin („TCM“, Traditional Chinese Medicine) zur Behandlung neurokognitiver Störungen und Dege...